SCHEMBL90849

SCHEMBL90849

CC(C)(C)S(=O)(=O)N[C@H]1CC[C@H](c2cc3c(F)c(N4CCOCC4)ccc3[nH]2)CC1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.37
IDH2 P48735 2/20 0.35
CCNT1 O60563 1/20 0.33
CDK9 P50750 1/20 0.33
LMNA P02545 5/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
ALDH1A1 P00352 3/20 0.33
MCOLN3 Q8TDD5 1/20 0.33
HPGD P15428 2/20 0.32
MAOB P27338 4/20 0.32
MAOA P21397 2/20 0.32
ESR1 P03372 1/20 0.32
PTGS1 P23219 1/20 0.32
CALML3 P27482 1/20 0.32
SDHA P31040 1/20 0.32
NPC1 O15118 1/20 0.32
BRAF P15056 1/20 0.32
TNNI3K Q59H18 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8528568 0.88 BRD4 (0.36) BRD4IDH2CCNT1CDK9LMNA
SCHEMBL8576076 0.86 USP30 (0.33) LMNAALDH1A1HPGD
SCHEMBL8545306 0.83 ESR1 (0.36) BRD4CCNT1CDK9LMNAALDH1A1
SCHEMBL8547161 0.80 IKBKB (0.44) CCNT1CDK9
SCHEMBL90919 0.78 BRD4 (0.34) BRD4SMN1; SMN2ALDH1A1HPGD
SCHEMBL8554397 0.72 DAO (0.36) CCNT1CDK9ALDH1A1
SCHEMBL90920 0.72 NPY5R (0.36) BRD4CCNT1CDK9
SCHEMBL91025 0.71 IKBKB (0.39) BRD4CCNT1CDK9BRAF
SCHEMBL8528320 0.70 NPY5R (0.45) BRD4IDH2
SCHEMBL91019 0.69 IKBKB (0.35) ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299066-B2 Compounds having NPY Y5 receptor antagonistic activity SHIONOGI & CO., LTD. (JP) 2012-10-30 US disclosed
US-20120130070-A1 COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-05-24 US disclosed
US-8129372-B2 Compounds having NPY Y5 receptor antagonistic activity SHIONOGI & CO., LTD. (JP) 2012-03-06 US disclosed
US-20110028468-A1 COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY Shinonogi & Co., Ltd (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130070-A1 COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY NPY5R, NPY1R, NPY2R BRD4 482/4885IDH2 3870/4885CCNT1 3615/4885
US-20110028468-A1 COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY NPY5R, NPY1R, NPY2R BRD4 482/4885IDH2 3870/4885CCNT1 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.